| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 21/11/2024 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VIRI | Virios Therapeutics Inc |
| 08/11/2024 | 14:15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:VIRI | Virios Therapeutics Inc |
| 17/10/2024 | 22:30 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:VIRI | Virios Therapeutics Inc |
| 15/10/2024 | 22:19 | Edgar (US Regulatory) | Form SC 13D - General Statement of Acquisition of Beneficial Ownership | NASDAQ:VIRI | Virios Therapeutics Inc |
| 07/10/2024 | 14:06 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:VIRI | Virios Therapeutics Inc |
| 07/10/2024 | 13:05 | GlobeNewswire Inc. | Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) | NASDAQ:VIRI | Virios Therapeutics Inc |
| 08/08/2024 | 15:15 | GlobeNewswire Inc. | Virios Therapeutics Announces Second Quarter 2024 Financial Results | NASDAQ:VIRI | Virios Therapeutics Inc |
| 01/08/2024 | 15:41 | GlobeNewswire Inc. | Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 | NASDAQ:VIRI | Virios Therapeutics Inc |
| 23/07/2024 | 15:15 | GlobeNewswire Inc. | Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center | NASDAQ:VIRI | Virios Therapeutics Inc |
| 22/05/2024 | 19:30 | GlobeNewswire Inc. | Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study | NASDAQ:VIRI | Virios Therapeutics Inc |
| 20/05/2024 | 22:05 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] | NASDAQ:VIRI | Virios Therapeutics Inc |
| 20/05/2024 | 02:53 | GlobeNewswire Inc. | Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study | NASDAQ:VIRI | Virios Therapeutics Inc |
| 17/05/2024 | 22:10 | GlobeNewswire Inc. | Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study | NASDAQ:VIRI | Virios Therapeutics Inc |
| 09/05/2024 | 13:45 | GlobeNewswire Inc. | Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:VIRI | Virios Therapeutics Inc |
| 02/05/2024 | 15:15 | GlobeNewswire Inc. | Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 | NASDAQ:VIRI | Virios Therapeutics Inc |
| 26/03/2024 | 14:15 | GlobeNewswire Inc. | Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID | NASDAQ:VIRI | Virios Therapeutics Inc |
| 08/03/2024 | 23:00 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] | NASDAQ:VIRI | Virios Therapeutics Inc |
| 01/03/2024 | 15:10 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:VIRI | Virios Therapeutics Inc |
| 29/02/2024 | 15:15 | GlobeNewswire Inc. | Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:VIRI | Virios Therapeutics Inc |
| 28/02/2024 | 19:14 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VIRI | Virios Therapeutics Inc |
| 28/02/2024 | 15:15 | GlobeNewswire Inc. | Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones | NASDAQ:VIRI | Virios Therapeutics Inc |
| 02/02/2024 | 22:31 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:VIRI | Virios Therapeutics Inc |
| 22/01/2024 | 15:33 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:VIRI | Virios Therapeutics Inc |
| 22/01/2024 | 15:00 | GlobeNewswire Inc. | Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID | NASDAQ:VIRI | Virios Therapeutics Inc |
| 02/01/2024 | 13:05 | GlobeNewswire Inc. | Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID | NASDAQ:VIRI | Virios Therapeutics Inc |
| 13/11/2023 | 13:05 | GlobeNewswire Inc. | Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:VIRI | Virios Therapeutics Inc |
| 06/11/2023 | 13:05 | GlobeNewswire Inc. | Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 | NASDAQ:VIRI | Virios Therapeutics Inc |
| 12/10/2023 | 13:05 | GlobeNewswire Inc. | Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023 | NASDAQ:VIRI | Virios Therapeutics Inc |
| 18/09/2023 | 13:05 | GlobeNewswire Inc. | Virios Therapeutics Announces Termination of At-The-Market Sales Agreement | NASDAQ:VIRI | Virios Therapeutics Inc |
| 12/09/2023 | 13:05 | GlobeNewswire Inc. | Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023 | NASDAQ:VIRI | Virios Therapeutics Inc |